Near infrared cerebral oxygenation monitoring

J. M. Murkin

Professor of Anesthesiology, Director of Cardiac Anesthesiology Research, University of Western Ontario, London, Ontario, Canada

Applied Cardiopulmonary Pathophysiology 13: 152-154, 2009

In a manner analogous to pulse oximetry, near-infrared spectroscopic (NIRS) light can be used to measure cerebral tissue oxygen saturation. All clinical NIRS devices detect changes in the concentrations of oxygenated and de-oxygenated hemoglobin but are unable to distinguish between arterial and venous concentrations.

**Cortical near infrared spectroscopy**

This technique employs principles of optical spectrophotometry which exploits the fact that biological material including skull, is relatively transparent in the near infrared range. Light transmission depends on a combination of reflectance, scattering and absorption effects. Reflectance is primarily a function of the angle of the light beam to the tissue surface, while scattering decreases with increasing wavelength, favouring transmission of shorter near-infrared (NIR) light (650-1100 nm). Absorption occurs at specific wavelengths, determined by the molecular properties of the materials in the light path. Above 1300 nm water absorbs all photons over a pathlength of a few millimetres, while below 700 nm, increasing light scattering and intense absorption bands of hemoglobin (Hb) prevent transmission. In the 700-1300 nm range, however, NIR light penetrates tissue several centimetres [1]. The absorption spectra of oxyhemoglobin (HbO₂) ranges from 800-850 nm, deoxyhemoglobin ranges from 650-800 nm, and CaO₂ has a broad peak at 820-840 nm [2].

In order to compensate for extracerebral tissue, most common techniques employ either spatial resolution or temporal resolution. Spatial resolution commonly involves differentially spaced receiving optodes with the signal from the closer receiver measuring more superficial tissue and distal optode measuring both superficial and deeper tissues and cortical oxy-

**NIRS devices**

NIRS devices employ sequentially pulsed light-emitting diodes or direct laser light to emit NIR light transcutaneously and detect returning photons either by photodiodes or fibre optic transmission to a photomultiplier and can be used to determine the oxygen saturation status of cerebral tissue. There are currently two FDA-cleared cerebral oximeters INVOS 5100 (Somanetics Corporation, Troy, MI) and Foresight (CAS Medical Systems, Branford, CT). There appears to be some difference in approach between these devices. INVOS is a dual-channel continuous wave spatially resolved spectrometer which has been designed to measure change in regional oxygen saturation (rSO₂). Using a proprietary subtraction algorithm, this device uses light emitting diode (LED) at 730 nm and 810 nm and differentially spaced receiving optodes to assess bi-frontal cortical oxygenation.

Alternatively, Foresight is designed to measure absolute brain tissue oxygen saturation. This oximeter utilizes continuous wavelengths at 690 nm, 780 nm, 805 nm and 850 nm to derive SO₂. To date there have been no direct comparisons between these two technologies. A third device, NIRO-300 (Hamamatsu Photonics KH, Hamamatsu City, Japan), which is currently for investigational use only, employs spatially resolved spectroscopy to measure light attenuation as a function of source-detector separation which is theo-
Near infrared cerebral oxygenation monitoring

Retically not influenced by photon path length and can thus potentially give a measure of absolute tissue oxygen saturation [4].

Using computed tomographic assessment of skull thickness (t-skull), cerebrospinal fluid area (a-CSFL) and hemoglobin concentration, NIRO-100 was compared with INVOS 4100 in a recent study of 103 cardiac surgical and neurosurgical patients [4]. This demonstrated that rSO2 values were potentially influenced by hemoglobin concentration, t-skull and a-CSFV. The authors did indicate that there was a potential confound in this evaluation as there was no assessment of superficial tissue attenuation of NIR light, for which INVOS employs a subtraction algorithm as compensation [4]. In an in vivo animal study comparing sensitivity between INVOS 5100 and NIRO-300 (Hamamatsu Photonics KH, Hamamatsu City, Japan), a swine model involving induced events including circulatory arrest, altered blood flow rate, core cooling, and re-warming during CPB was employed [5]. In this comparison the authors concluded that NIRO-300 measured a higher tissue oxygen index (TOI) than INVOS during low concentrations of oxygenated hemoglobin and lower values during high concentrations of oxygenated hemoglobin and this may indicate a difference in sensitivity between these devices.

Confounds

Oxygen saturation values in non-metabolizing tissue may be high or low. Tissue oxygen saturation may be near normal in dead or non-metabolizing brain because of sequestered cerebral venous blood in capillaries and venous capacitance vessels [6]. A misunderstanding of this fact has given rise to some concerns among investigators. Schwartz et al. examined rSO2 in 18 adult human cadavers and found values in one-third of the subjects that exceeded the lowest values that they had previously recorded in normal subjects raising concern regarding the validity of the rSO2 measurement [7]. Maeda et al. examined cerebral venous oxygen saturation during 214 autopsies and found the values to range from 0.3 to 95.1% apparently as a consequence of total hemoglobin content, cause of death and cadaver storage conditions [8].

Clinical studies

Previous studies have indicated a positive predictive value between low rSO2 and adverse CNS outcomes [9]. The use of cerebral oximetry identifies a number of otherwise unrecognized causes of cerebral hypoperfusion both during conventional CPB [10], and during beating heart surgery [11]. Various causes of cerebral hypoperfusion including inadvertent positioning of the head turned to extreme left side, cannula-obstructed venous outflow from brain, hypocapnia, low perfusion pressure, inadequate hemoglobin concentration, have all been detected and successfully treated by applied rSO2 oximetry [12,13]. During beating heart procedures compromised cerebral perfusion can occur relatively frequently with an incidence nearly twice that occurring during CPB, as demonstrated using jugular oximetry in a randomized clinical study of 187 patients [14]. In a series of 550 beating heart patients combined EEG and cerebral oximetry identified episodes of cerebral ischemia in 15% of patients, which were treated by a combination of pharmacologically-improved cardiac output, increased perfusion pressure and cardiac repositioning [15].

The use of rSO2 has demonstrated correlation between CAB patients having low rSO2 values and cognitive dysfunction [16], prolonged hospital stay [17], and most recently, perioperative cerebrovascular accident (CVA) [18]. Dunham et al. showed that rSO2 values correlated with cerebral perfusion pressure, Glasgow Outcome Score and mortality in patients with traumatic brain injuries [19], and several other groups have demonstrated the ability of rSO2 to provide an early warning of cerebral ischemia [20-22]. Studies are also beginning to appear assessing the utility of Fore-sight as a clinical monitor [23].

In a recent large non-randomized series of 1034 cardiac surgical patients reported by Goldman and colleagues, a significant reduction in perioperative stroke rate, from 2.01% to 0.97%, was observed in patients in whom rSO2 cerebral oximetry was used to optimize and maintain intraoperative cerebral oxygenation in comparison to an untreated comparator group of 1245 similar patients operated on in the immediately preceding 18 month interval [18].

In a recent prospective, randomized blinded study by Murkin et al. in 200 patients undergoing coronary artery grafting, it was demonstrated that treatment of declining rSO2 prevented prolonged desaturations and was associated with a shorter ICU stay and a significantly reduced incidence of major organ morbidity or
mortality. The intervention protocol undertaken to return rSO₂ to baseline resulted in a rapid improvement in rSO₂ in most cases and did not add undue risk to the patient [24]. There were also numerically fewer clinical CVA in monitored patients directionally consistent with previous studies [18].

Summary

While none of the interventions undertaken to correct decreases in rSO₂ fall outside the range of good clinical practice, it is clear in that the absence of feedback from a specific indicator of end-organ compromise (e.g., cerebral desaturations), the ability of the clinician to detect and optimize otherwise silent but potentially adverse perturbations in various clinical parameters remains limited. Non-invasive cerebral oximetry represents a potentially important new monitoring modality. Further clinical outcomes studies are necessary to define the optimal role of this monitoring modality.

References

23. Fischer GW, Reich D, Plesitis KA, Griepp RB. Results using absolute cerebral oximetry monitoring suggest the need for tailored patient management during cardiac surgery. Heart Surg Forum 2006 (abstract)

Address for corresponding: John M. Murkin, M.D., FRCPC, Professor of Anesthesiology, Director of Cardiac Anesthesiology Research, University of Western Ontario, Ontario, 339 Windermere Road, London, ON N6A 5A5, Canada, E-Mail: jmurkin@uwo.ca